Compare ESPR & INN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESPR | INN |
|---|---|---|
| Founded | 2008 | N/A |
| Country | United States | United States |
| Employees | N/A | 78 |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 814.3M | 671.9M |
| IPO Year | 2013 | N/A |
| Metric | ESPR | INN |
|---|---|---|
| Price | $3.16 | $6.81 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 4 | 2 |
| Target Price | ★ $8.75 | $4.50 |
| AVG Volume (30 Days) | ★ 9.6M | 2.0M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 6.41% |
| EPS Growth | ★ 60.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $403,135,000.00 | N/A |
| Revenue This Year | N/A | $2.00 |
| Revenue Next Year | $12.81 | $1.96 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 21.31 | N/A |
| 52 Week Low | $0.95 | $3.98 |
| 52 Week High | $4.18 | $6.78 |
| Indicator | ESPR | INN |
|---|---|---|
| Relative Strength Index (RSI) | 67.43 | 73.94 |
| Support Level | $3.11 | $4.15 |
| Resistance Level | $3.18 | N/A |
| Average True Range (ATR) | 0.02 | 0.23 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 62.50 | 97.40 |
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.
Summit Hotel Properties Inc is a U.S.-based hotel investment company focusing on select-service hotels in the upscale and upper-midscale properties in the U.S. Substantially all of Summit's assets are held and operated by its Operating Partnership, Summit Hotel OP, LP, in which the company holds general and limited partnership interests. The firm has one segment in activities related to investing in real estate. Summit's revenue streams include Room and Other hotel operations revenue. Room comprises the majority of total revenues. The company's hotels are located in various markets, such as corporate offices, retail centers, airports, state capitols, convention centers, and leisure attractions. Summit's hotels operate under brands, including Marriott, Hilton, Hyatt, and Holiday Inn.